Project: Investigating NOvel VAluable bio-Therapeutics and Expression systems
The production of IgGs has revolutionized the biotech industry with products used for the treatment of cancer and immune disorders. IgGs represent just one potential class of biotherapeutic and yet few other classes (with potential to treat specific diseases) have been as well developed due to challenges in their manufacture. Challenging new recombinant proteins (rPs) of commercial and clinical value include fusion proteins (for novel disease targeting), IgA (the most abundant Ig isoform, for treatment of IgA deficiencies, cancer) and secreted mucins (for disease therapy, vaccines). This project will develop new animal (CHO) and plant (tobacco) cell and glycosylation expression technologies, and establish bioprocesses, for the production of these difficult to express novel rPs that have the potential to open up new targets and treatments that resist current therapies. The consortium will seek protection of IP rights for the new technologies and to develop these with interested parties.
| Acronym | INNOVATE |
| Website | visit project website |
| Network | ERA-IB-2 |
| Call | 4th ERA-IB Joint Call |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| Fraunhofer Society for the Advancement of Applied Research - Fraunhofer Institute for Molecular Biology and Applied Ecology | Germany | ||
| Instituto de Biologia Experimental e Tecnológica | Portugal | ||
| Instituto de Tecnologia Química e Biológica António Xavier, New University of Lisbon | Portugal | ||
| Lonza Biologics PLC | United Kingdom | ||
| University of Kent | Coordinator | United Kingdom |